206 related articles for article (PubMed ID: 30367145)
41. [Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences].
Yuan J; Wu CW; Liu ZJ; Wei XY; Li K
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):580-5. PubMed ID: 21122408
[TBL] [Abstract][Full Text] [Related]
42. Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014.
Takagi Y; Hosomi Y; Oshita F; Okamoto H; Seki N; Minato K; Aono H; Yamada K; Okuma Y; Hida N; Sakamoto T; Miura Y; Yomota M; Satoh A; Kunitoh H; Sakamaki K; Shibuya M; Watanabe K
BMC Cancer; 2015 Oct; 15():740. PubMed ID: 26481215
[TBL] [Abstract][Full Text] [Related]
43. Bevacizumab in advanced lung cancer: state of the art.
Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
[TBL] [Abstract][Full Text] [Related]
44. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
45. A bivalent cyclic RGD-siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts.
Liao L; Cen B; Li G; Wei Y; Wang Z; Huang W; He S; Yuan Y; Ji A
Drug Deliv; 2021 Dec; 28(1):1432-1442. PubMed ID: 34236267
[TBL] [Abstract][Full Text] [Related]
46. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
47. Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC.
Zhao X; Wen X; Wei W; Su Y; You J; Gong L; Zhang Z; Wang M; Xiao J; Wei X; Wang C
Cancer Biomark; 2017 Dec; 21(1):169-177. PubMed ID: 29036790
[TBL] [Abstract][Full Text] [Related]
48. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O; Rothschild SI; Li Q; Matter-Walstra K; Zippelius A; Betticher DC; Früh M; Stahel RA; Cathomas R; Rauch D; Pless M; Peters S; Froesch P; Zander T; Schneider M; Biaggi C; Mach N; Ochsenbein AF;
Clin Lung Cancer; 2017 May; 18(3):303-309. PubMed ID: 27993482
[TBL] [Abstract][Full Text] [Related]
49. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy.
Ohara T; Noma K; Urano S; Watanabe S; Nishitani S; Tomono Y; Kimura F; Kagawa S; Shirakawa Y; Fujiwara T
Int J Cancer; 2013 Jun; 132(11):2705-13. PubMed ID: 23161652
[TBL] [Abstract][Full Text] [Related]
50. An-te-xiao capsule inhibits tumor growth in non-small cell lung cancer by targeting angiogenesis.
Han L; Wang JN; Cao XQ; Sun CX; Du X
Biomed Pharmacother; 2018 Dec; 108():941-951. PubMed ID: 30372906
[TBL] [Abstract][Full Text] [Related]
51. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
[TBL] [Abstract][Full Text] [Related]
52. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
[TBL] [Abstract][Full Text] [Related]
53. New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Curr Pharm Des; 2015; 21(32):4763-72. PubMed ID: 26219615
[TBL] [Abstract][Full Text] [Related]
54. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
55. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
56. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
57. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
[TBL] [Abstract][Full Text] [Related]
58. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
[TBL] [Abstract][Full Text] [Related]
59. Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imaging.
Zhang Q; Du Y; Xue Z; Chi C; Jia X; Tian J
PLoS One; 2014; 9(1):e85559. PubMed ID: 24416426
[TBL] [Abstract][Full Text] [Related]
60. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]